Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 24Gastrointestinal 21NET 14Thoracic 4CNS 4Breast 4Gynecologic 3Genitourinary 3Sarcoma 2Tumor-Agnostic 1Other solid neoplasm 1Other hematologic neoplasm 1Other 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Octreotide × Tumor-Agnostic × Clear all
NCT00182754 2017-04-11

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

Alliance for Clinical Trials in Oncology

Phase 3 Completed
33 enrolled 9 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡